Cargando…

The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia—Subanalysis of the DALI Study

CONTEXT: Neonatal hypoglycaemia (NH) is the most common metabolic problem in infants born of mothers with gestational diabetes. Plasma glycated CD59 (pGCD59) is an emerging biomarker that has shown potential in identifying women at risk of developing gestational diabetes. The aim of this study was t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogdanet, Delia, Luque-Fernandez, Miguel Angel, Toth-Castillo, Michelle, Desoye, Gernot, O’Shea, Paula M, Dunne, Fidelma P, Halperin, Jose A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681607/
https://www.ncbi.nlm.nih.gov/pubmed/36054347
http://dx.doi.org/10.1210/clinem/dgac498
_version_ 1784834652887842816
author Bogdanet, Delia
Luque-Fernandez, Miguel Angel
Toth-Castillo, Michelle
Desoye, Gernot
O’Shea, Paula M
Dunne, Fidelma P
Halperin, Jose A
author_facet Bogdanet, Delia
Luque-Fernandez, Miguel Angel
Toth-Castillo, Michelle
Desoye, Gernot
O’Shea, Paula M
Dunne, Fidelma P
Halperin, Jose A
author_sort Bogdanet, Delia
collection PubMed
description CONTEXT: Neonatal hypoglycaemia (NH) is the most common metabolic problem in infants born of mothers with gestational diabetes. Plasma glycated CD59 (pGCD59) is an emerging biomarker that has shown potential in identifying women at risk of developing gestational diabetes. The aim of this study was to assess the association between early maternal levels of pGCD59 and NH. OBJECTIVE: The aim of this study was to assess the association between early pregnancy maternal levels of plasma glycated CD59 (pGCD59) and neonatal hypoglycemia (NH). METHODS: This is an observational study of pregnant women with a prepregnancy body mass index (BMI) greater than or equal to 29 screened for eligibility to participate in the Vitamin D and Lifestyle Intervention for Gestational Diabetes (DALI) trial. This analysis included 399 pregnancies. Levels of pGCD59 were measured in fasting maternal samples taken at the time of a 75-g, 2-hour oral glucose tolerance test performed in early pregnancy (< 20 weeks). NH, the study outcome, was defined as a heel-prick capillary glucose level of less than 2.6 mmol/L within 48 hours of delivery. RESULTS: We identified 30 infants with NH. Maternal levels of pGCD59 in early pregnancy were positively associated with the prevalence of NH (one-way analysis of variance, P < .001). The odds of NH were higher in infants from mothers in tertile 3 of pGCD59 levels compared to those from mothers in tertile 1 (odds ratio [OR]: 2.41; 95% CI, 1.03-5.63). However, this was attenuated when adjusted for maternal BMI (OR: 2.28; 95% CI, 0.96-5.43). The cross-validated area under the curve (AUC) was 0.64 (95% CI, 0.54-0.74), and adjusted for maternal BMI, age, and ethnicity, the AUC was 0.70 (95% CI, 0.56-0.78). CONCLUSION: Although pGCD59 levels in early pregnancy in women with BMI greater than or equal to 29 are associated with NH, our results indicate that this biomarker by itself is only a fair predictor of NH.
format Online
Article
Text
id pubmed-9681607
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96816072022-11-25 The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia—Subanalysis of the DALI Study Bogdanet, Delia Luque-Fernandez, Miguel Angel Toth-Castillo, Michelle Desoye, Gernot O’Shea, Paula M Dunne, Fidelma P Halperin, Jose A J Clin Endocrinol Metab Clinical Research Article CONTEXT: Neonatal hypoglycaemia (NH) is the most common metabolic problem in infants born of mothers with gestational diabetes. Plasma glycated CD59 (pGCD59) is an emerging biomarker that has shown potential in identifying women at risk of developing gestational diabetes. The aim of this study was to assess the association between early maternal levels of pGCD59 and NH. OBJECTIVE: The aim of this study was to assess the association between early pregnancy maternal levels of plasma glycated CD59 (pGCD59) and neonatal hypoglycemia (NH). METHODS: This is an observational study of pregnant women with a prepregnancy body mass index (BMI) greater than or equal to 29 screened for eligibility to participate in the Vitamin D and Lifestyle Intervention for Gestational Diabetes (DALI) trial. This analysis included 399 pregnancies. Levels of pGCD59 were measured in fasting maternal samples taken at the time of a 75-g, 2-hour oral glucose tolerance test performed in early pregnancy (< 20 weeks). NH, the study outcome, was defined as a heel-prick capillary glucose level of less than 2.6 mmol/L within 48 hours of delivery. RESULTS: We identified 30 infants with NH. Maternal levels of pGCD59 in early pregnancy were positively associated with the prevalence of NH (one-way analysis of variance, P < .001). The odds of NH were higher in infants from mothers in tertile 3 of pGCD59 levels compared to those from mothers in tertile 1 (odds ratio [OR]: 2.41; 95% CI, 1.03-5.63). However, this was attenuated when adjusted for maternal BMI (OR: 2.28; 95% CI, 0.96-5.43). The cross-validated area under the curve (AUC) was 0.64 (95% CI, 0.54-0.74), and adjusted for maternal BMI, age, and ethnicity, the AUC was 0.70 (95% CI, 0.56-0.78). CONCLUSION: Although pGCD59 levels in early pregnancy in women with BMI greater than or equal to 29 are associated with NH, our results indicate that this biomarker by itself is only a fair predictor of NH. Oxford University Press 2022-09-02 /pmc/articles/PMC9681607/ /pubmed/36054347 http://dx.doi.org/10.1210/clinem/dgac498 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Research Article
Bogdanet, Delia
Luque-Fernandez, Miguel Angel
Toth-Castillo, Michelle
Desoye, Gernot
O’Shea, Paula M
Dunne, Fidelma P
Halperin, Jose A
The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia—Subanalysis of the DALI Study
title The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia—Subanalysis of the DALI Study
title_full The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia—Subanalysis of the DALI Study
title_fullStr The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia—Subanalysis of the DALI Study
title_full_unstemmed The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia—Subanalysis of the DALI Study
title_short The Role of Early Pregnancy Maternal pGCD59 Levels in Predicting Neonatal Hypoglycemia—Subanalysis of the DALI Study
title_sort role of early pregnancy maternal pgcd59 levels in predicting neonatal hypoglycemia—subanalysis of the dali study
topic Clinical Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681607/
https://www.ncbi.nlm.nih.gov/pubmed/36054347
http://dx.doi.org/10.1210/clinem/dgac498
work_keys_str_mv AT bogdanetdelia theroleofearlypregnancymaternalpgcd59levelsinpredictingneonatalhypoglycemiasubanalysisofthedalistudy
AT luquefernandezmiguelangel theroleofearlypregnancymaternalpgcd59levelsinpredictingneonatalhypoglycemiasubanalysisofthedalistudy
AT tothcastillomichelle theroleofearlypregnancymaternalpgcd59levelsinpredictingneonatalhypoglycemiasubanalysisofthedalistudy
AT desoyegernot theroleofearlypregnancymaternalpgcd59levelsinpredictingneonatalhypoglycemiasubanalysisofthedalistudy
AT osheapaulam theroleofearlypregnancymaternalpgcd59levelsinpredictingneonatalhypoglycemiasubanalysisofthedalistudy
AT dunnefidelmap theroleofearlypregnancymaternalpgcd59levelsinpredictingneonatalhypoglycemiasubanalysisofthedalistudy
AT halperinjosea theroleofearlypregnancymaternalpgcd59levelsinpredictingneonatalhypoglycemiasubanalysisofthedalistudy
AT bogdanetdelia roleofearlypregnancymaternalpgcd59levelsinpredictingneonatalhypoglycemiasubanalysisofthedalistudy
AT luquefernandezmiguelangel roleofearlypregnancymaternalpgcd59levelsinpredictingneonatalhypoglycemiasubanalysisofthedalistudy
AT tothcastillomichelle roleofearlypregnancymaternalpgcd59levelsinpredictingneonatalhypoglycemiasubanalysisofthedalistudy
AT desoyegernot roleofearlypregnancymaternalpgcd59levelsinpredictingneonatalhypoglycemiasubanalysisofthedalistudy
AT osheapaulam roleofearlypregnancymaternalpgcd59levelsinpredictingneonatalhypoglycemiasubanalysisofthedalistudy
AT dunnefidelmap roleofearlypregnancymaternalpgcd59levelsinpredictingneonatalhypoglycemiasubanalysisofthedalistudy
AT halperinjosea roleofearlypregnancymaternalpgcd59levelsinpredictingneonatalhypoglycemiasubanalysisofthedalistudy